Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 407.56M P/E - EPS this Y 29.00% Ern Qtrly Grth -
Income -319.25M Forward P/E -2.23 EPS next Y 52.60% 50D Avg Chg 7.00%
Sales 54.9M PEG -0.01 EPS past 5Y - 200D Avg Chg -26.00%
Dividend N/A Price/Book 1.15 EPS next 5Y 45.80% 52W High Chg -55.00%
Recommedations 2.70 Quick Ratio 0.53 Shares Outstanding 193.91M 52W Low Chg 38.00%
Insider Own 0.44% ROA -36.24% Shares Float 193.13M Beta 0.80
Inst Own 43.40% ROE -186.70% Shares Shorted/Prior 48.40M/41.14M Price 3.83
Gross Margin -38.67% Profit Margin - Avg. Volume 4,213,451 Target Price 2.75
Oper. Margin -548.99% Earnings Date Nov 5 Volume 2,991,750 Change 2.68%
About bluebird bio, Inc.

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company's product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. Its clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.

bluebird bio, Inc. News
10/04/24 bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09/27/24 Bluebird: Q2 Earnings Snapshot
09/27/24 bluebird bio Announces Completion of its Q2 2024 Form 10-Q Filing
09/24/24 Gene Therapy-Focused Bluebird Bio Restructures, Cuts Is Workforce By 25%, Seeks To Breakeven Next Year
09/24/24 bluebird bio Initiates Restructuring Intended to Optimize Cost Structure and Enable Quarterly Cash Flow Break-Even in the Second Half of 2025
09/13/24 bluebird bio Announces Completion of its Restatement and filing of its 2023 Form 10-K and Q1 2024 Form 10-Q
08/28/24 FDA will not meet ahead of bluebird bio’s sickle cell disease gene therapy PDUFA date
08/28/24 bluebird bio Announces September Investor Events
08/23/24 bluebird bio Announces Receipt of Expected Notices from Nasdaq
08/14/24 bluebird bio Reports Second Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance
08/12/24 bluebird bio Announces Second Quarter 2024 Results Call Date
08/02/24 bluebird bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
07/29/24 With 57% ownership of the shares, bluebird bio, Inc. (NASDAQ:BLUE) is heavily dominated by institutional owners
07/23/24 HHS gives thumbs down to bluebird’s fertility support programme
07/03/24 bluebird bio Reports Inducement Grant to CFO James Sterling Under Nasdaq Listing Rule 5635(c)(4)
06/02/24 2Flo Ventures Announces Addition of Renowned Life Sciences Executive Charlotte Jones-Burton, MD, MS as a Partner
05/29/24 bluebird bio Appoints O. James Sterling as Chief Financial Officer
05/17/24 BLUE vs. CRSP: Why Are These Stocks Moving in Opposite Directions?
05/16/24 Is Bluebird Bio Stock a Buy?
BLUE Chatroom

User Image Bearssuckbutt Posted - 5 hours ago

$BLUE last year this time it was over $4. now with 80 pts, more QTC, revenue rolling in, SCD act and its $.50. unbelievable. when in fact if and when big money and pharma realizes this is a Gem it be in $CRSP level. look in past how $OCGN and $SMMT rallied on rumors, hopes and phase trial results. this has 3 FDA approved gene therapies. $10 should be minimum BO

User Image The_Dream_Team Posted - 8 hours ago

$BLUE A buy signal was issued from a pivot bottom point on Friday, September 20, 2024, and so far it has risen 21.23%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Volume is rising along with the price. This is considered to be a good technical signal.

User Image The_Dream_Team Posted - 8 hours ago

$BLUE Since the stock is closer to the support from accumulated volume at $0.567 (0.47%) than the resistance at $0.692 (21.39%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..

User Image The_Dream_Team Posted - 8 hours ago

$BLUE possible swing 18% Monday between high and low 👀

User Image The_Dream_Team Posted - 8 hours ago

$BLUE Trading Expectations (BLUE) For The Upcoming Trading Day Of Monday 7th For the upcoming trading day on Monday, 7th we expect bluebird bio to open at $0.555, and during the day (based on 14 day Average True Range), to move between $0.516 and $0.624, which gives a possible trading interval of +/-$0.0541 (+/-9.50%) up or down from last closing price. If bluebird bio takes out the full calculated possible swing range there will be an estimated 18.99% move between the lowest and the highest trading price during the day.

User Image Oowen Posted - 9 hours ago

@coolelel @Gepram $blue has fda approved products, not just one, two i believe, i got out @$8 a couple of years ago, still lost over 60%.

User Image jjpk Posted - 9 hours ago

$BLUE am I reading correctly that these shower of cunts are giving themselves shares again. That couldn't be true

User Image lzwa Posted - 23 hours ago

$CRSP $VRTX $BLUE https://www.reuters.com/business/healthcare-pharmaceuticals/why-gene-therapy-sickle-cell-is-slow-catch-with-patients-2024-09-28/

User Image Oowen Posted - 1 day ago

@Gepram there many bios like that, $ALLK , $BLUE, etc.

User Image MsB_buyHighsellLow Posted - 1 day ago

$BLUE BO for $5+

User Image PennyConnection1 Posted - 1 day ago

$BLUE not a bad way to end week with a 10% day, see you all next week! Bottom seems to be in, can’t say the CEO can mess things up any further down here… but then again his track record says otherwise so 🤷‍♂️

User Image HuntingBenjmins Posted - 1 day ago

$BLUE When is the vote on the reverse split? What date?

User Image Shad002 Posted - 1 day ago

$BLUE

User Image BroadwayJoe12 Posted - 1 day ago

$BLUE I’m here now

User Image JoeTheCheap Posted - 1 day ago

$BLUE Praying hard for a weekend buyout at $3 or greater!!!

User Image PennyConnection1 Posted - 1 day ago

$PRCH any of you porchers got any $BLUE lately ?

User Image RoobinHood Posted - 1 day ago

$BLUE

User Image Garlic1969 Posted - 1 day ago

@Schizoo I'm in... $BLUE And maybe this conversation is the beginning of a beautiful friendship (Casablanca) ! Hahahaha

User Image The_Dream_Team Posted - 1 day ago

$BLUE I smell a poke in the eye over a buck soon. Anybody else smell that???

User Image dkwast Posted - 1 day ago

$BLUE high lows, let’s break that resistance

User Image The_Dream_Team Posted - 1 day ago

$BLUE Monday a run to .75 seems legit

User Image blueb22 Posted - 1 day ago

$BLUE - One thing which is under wrap is what is going on with the CMS negotiations for OBA and Price for Lyfgenia, which has started in summer and had timeline to finish by mid-Nov. But that means BLUE will already know lot more details like how many states intending to enroll, how many patients they are intending to treat each year, what is the Price and all major terms of OBA by mid-October or at the most by end of October. We will not know those anytime soon, but potential buyers (large pharma) who are interested will know as soon as in next couple of week. And this is BIG piece of this whole Lyfgenia opportunity & potential puzzle. We are so close to this floodgates of new SCD patients who are under Medicaid coverage, and the whole intention of this CMS SCD roll-out in Jan2025 is to increase access to these two SCD gene therapies. Good Luck Longs! 👍 Fingers crossed 🤞

User Image The_Dream_Team Posted - 1 day ago

$BLUE

User Image blueb22 Posted - 1 day ago

$BLUE - what I am looking forward to in Nov Q3 ER call: They are on target or exceeding the 40 patients starts in Q4 (there is no question or doubt that they will reach 40, but it could be that they could exceed that by 5) We know revenue will be low in Q3 (and also in Q4), so I am not worried if it is from 10 patients or from 7 patients infusions. In 2nd week of Nov they will be able to provide accurate Q4 start numbers as in 2nd half of December there will be hardly any new schedules for either cell collections or infusions. But, I am most interested in them providing numbers on how many are scheduled for cell collections in 2025 (or upto Q12025 to be more specific), as most of the new schedules now onwards would be for Q1 2025.

User Image The_Dream_Team Posted - 1 day ago

$BLUE I heard partnerships are coming

User Image blueb22 Posted - 1 day ago

$BLUE - it brutal market like Yesterday's and today BLUE is up and is in consistent upward trend (no way it is pump and dump kind of move). This is good Sign. And I Think, Hope, and Pray that this slow upward trend will continue for weeks to come to reach the desired level of around $3-4.

User Image Greedy_communist Posted - 1 day ago

$BLUE easy folks, keep your risk in check with this one.

User Image blueb22 Posted - 1 day ago

$BLUE - something may be in work like Royalty deal or ex-US deal (sale or partnership), and this 2nd is very much possible if they want to go that route as opposed to whole BO route. If they go one of these route, ofcourse they will be able to address the cash gap issue and may be even able to pay of Hercules debt (which I increasingly think they are planning to do).

User Image Nikkosi Posted - 1 day ago

$BLUE She on the move.

User Image lasmanoz Posted - 1 day ago

$BLUE whats going on here

Analyst Ratings
Wells Fargo Equal-Weight Sep 25, 24
Cantor Fitzgerald Neutral Sep 16, 24
B of A Securities Buy Aug 15, 24
RBC Capital Sector Perform Aug 15, 24
Barclays Overweight Aug 15, 24
Baird Outperform Aug 15, 24
JP Morgan Neutral Aug 15, 24
RBC Capital Sector Perform Mar 27, 24
Wells Fargo Equal-Weight Mar 27, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Klima Thomas J See Remarks See Remarks Feb 05 Sell 0.9025 2,714 2,449 129,413 02/06/24
Vittiglio Joseph Chief Business & Leg.. Chief Business & Legal Officer Feb 05 Sell 0.9025 5,217 4,708 44,783 02/06/24
Obenshain Andrew President and CEO President and CEO Feb 05 Sell 0.9025 1,879 1,696 286,093 02/06/24
Obenshain Andrew President and CEO President and CEO Aug 10 Sell 3.5416 16,929 59,956 291,941 08/10/23
Obenshain Andrew President and CEO President and CEO Jan 11 Sell 7.8043 3,178 24,802 242,690 01/13/23
Colvin Richard A Chief Medical Office.. Chief Medical Officer Jan 11 Sell 7.8043 557 4,347 74,231 01/13/23
Leschly Nick Director Director Jan 11 Sell 7.8043 4,290 33,480 280,149 01/13/23
Colvin Richard A Chief Medical Office.. Chief Medical Officer Nov 04 Sell 6.4137 218 1,398 74,788 11/08/22
Obenshain Andrew President and CEO President and CEO Nov 04 Sell 6.4137 1,263 8,101 245,868 11/08/22
Cole Jason Chief Strategy & Fin.. Chief Strategy & Financial Off Aug 19 Sell 5.5286 14,194 78,473 189,546 08/23/22
Whitten Jessica Chief Accounting Off.. Chief Accounting Officer Jan 10 Sell 9.52 409 3,894 49,413 01/12/22
Cole Jason Chief Operating and Chief Operating and Jan 10 Sell 9.52 4,971 47,324 186,188 01/12/22
Leschly Nick Director Director Jan 10 Sell 9.52 7,437 70,800 281,330 01/12/22
Obenshain Andrew President and CEO President and CEO Jan 10 Sell 9.43 7,725 72,847 246,696 01/12/22
Leschly Nick President and CEO President and CEO Jan 08 Sell 45.06 10,428 469,886 87,263 01/08/21
Baird William D III Chief Financial Offi.. Chief Financial Officer Jan 08 Sell 45.11 949 42,809 22,797 01/08/21
FINGER ALISON CECILY Chief Commercial Off.. Chief Commercial Officer Jan 08 Sell 45.06 1,854 83,541 25,103 01/08/21
Davidson David Chief Medical Office.. Chief Medical Officer Jan 08 Sell 45.06 3,215 144,868 36,361 01/08/21
Cole Jason Chief Operating and Chief Operating and Jan 08 Sell 45.06 2,401 108,189 32,823 01/08/21
Smith-Farrell Joanne COO, Oncology COO, Oncology Jan 08 Sell 45.06 1,329 59,885 20,609 01/08/21
Gregory Philip D Chief Scientific Off.. Chief Scientific Officer Jan 08 Sell 45.06 2,799 126,123 33,007 01/08/21
FINGER ALISON CECILY Chief Commercial Off.. Chief Commercial Officer Dec 04 Sell 46.34 36 1,668 26,957 12/04/20
Smith-Farrell Joanne COO, Oncology COO, Oncology Dec 04 Sell 46.34 38 1,761 21,938 12/04/20
Cole Jason Chief Operating and Chief Operating and Dec 04 Sell 46.34 38 1,761 35,224 12/04/20
Gregory Philip D Chief Scientific Off.. Chief Scientific Officer Dec 04 Sell 46.34 59 2,734 35,806 12/04/20
Davidson David Chief Medical Office.. Chief Medical Officer Dec 04 Sell 46.34 64 2,966 39,576 12/04/20